Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Testosterone Enanthate · 1 trial · 4 indications
1-RM strength testing for 5 exercises will be performed using dynamic resistance exercise machines. Testing will be performed before treatment (baseline), at 3, 6, 9 and 12 months after treatment.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | testosterone enanthate |
| Arm 2 | EXPERIMENTAL | finasteride |
| Arm 3 | EXPERIMENTAL | testosterone enanthate + finasteride |
| Arm 4 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| Testosterone Enanthate | DRUG | 125 mg, i.m. injection, once/week, for 52 weeks |
| Finasteride | DRUG | 5 mg, oral, once/day, for 52 weeks |
| Placebo | OTHER | Placebo |
Inclusion Criteria: * Age \> 60 years males * Primary care at the Malcolm Randall VA Medical Center in Gainesville, Florida. * Consenting subjects who have a morning (between 6:00 AM and 10:00 AM) serum total testosterone 300 ng/dL or bioavailable testosterone concentration 70 ng/dL and no exclusio...
Testosterone Enanthate is used for male hypogonadism, a condition where the body does not produce enough testosterone. It is being investigated for its effects on muscle atrophy, sarcopenia, and benign prostate hypertrophy in men aged 60 years and older. The drug is currently in Phase 2 clinical development.
Testosterone Enanthate is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating male hypogonadism and related conditions.
Testosterone Enanthate is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The drug is being evaluated for its effects on male hypogonadism and associated conditions such as muscle atrophy and sarcopenia.
Testosterone Enanthate has one completed Phase 2 clinical trial registered under NCT00475501, titled '5-Alpha Reductase and Anabolic Effects of Testosterone.' The randomized, double-blind, placebo-controlled study enrolled 60 participants in the United States and investigated the drug's effects on male hypogonadism, muscle atrophy, sarcopenia, and benign prostate hypertrophy.
Testosterone Enanthate is a small molecule that works by supplementing testosterone levels in the body. It is designed to address testosterone deficiency in men with hypogonadism, potentially improving muscle mass and function. The drug's mechanism involves replacing or augmenting the body's natural testosterone to restore normal physiological levels.
Testosterone Enanthate is a form of testosterone, specifically an esterified version that allows for sustained release in the body. It is used to treat conditions related to low testosterone, such as male hypogonadism. The drug is being developed by Merck & Company, Inc. and is currently in Phase 2 clinical trials.